Notes to the Financial Statements (Group)
1 Product revenue information
| 2009 $m |
2008 $m |
2007 $m |
|
|---|---|---|---|
| Gastrointestinal: | |||
| Nexium | 4,959 | 5,200 | 5,216 |
| Losec/Prilosec | 946 | 1,055 | 1,143 |
| Others | 106 | 89 | 84 |
| Total Gastrointestinal | 6,011 | 6,344 | 6,443 |
| Cardiovascular: | |||
| Crestor | 4,502 | 3,597 | 2,796 |
| Seloken/Toprol-XL | 1,443 | 807 | 1,438 |
| Atacand | 1,436 | 1,471 | 1,287 |
| Zestril | 184 | 236 | 295 |
| Plendil | 241 | 268 | 271 |
| Onglyza™ | 11 | - | - |
| Others | 559 | 584 | 599 |
| Total Cardiovascular | 8,376 | 6,963 | 6,686 |
| Respiratory: | |||
| Symbicort | 2,294 | 2,004 | 1,575 |
| Pulmicort | 1,310 | 1,495 | 1,454 |
| Rhinocort | 264 | 322 | 354 |
| Oxis | 63 | 71 | 86 |
| Others | 201 | 236 | 242 |
| Total Respiratory | 4,132 | 4,128 | 3,711 |
| Oncology: | |||
| Arimidex | 1,921 | 1,857 | 1,730 |
| Casodex | 844 | 1,258 | 1,335 |
| Zoladex | 1,086 | 1,138 | 1,104 |
| Iressa | 297 | 265 | 238 |
| Faslodex | 262 | 249 | 214 |
| Nolvadex | 88 | 85 | 83 |
| Abraxane™ | - | 64 | 62 |
| Ethyol | 15 | 28 | 43 |
| Others | 5 | 10 | 10 |
| Total Oncology | 4,518 | 4,954 | 4,819 |
| Neuroscience: | |||
| Seroquel | 4,866 | 4,452 | 4,027 |
| Local anaesthetics | 599 | 605 | 557 |
| Zomig | 434 | 448 | 434 |
| Diprivan | 290 | 278 | 263 |
| Others | 48 | 54 | 59 |
| Total Neuroscience | 6,237 | 5,837 | 5,340 |
| Infection and Other: | |||
| Merrem | 872 | 897 | 773 |
| Synagis | 1,082 | 1,230 | 618 |
| FluMist | 145 | 104 | 53 |
| H1N1 Influenza Vaccine | 389 | - | - |
| Other Products | 143 | 220 | 270 |
| Total Infection and Other | 2,631 | 2,451 | 1,714 |
| Aptium Oncology | 393 | 395 | 402 |
| Astra Tech | 506 | 529 | 444 |
| Total | 32,804 | 31,601 | 29,559 |
